Epicrispr Biotechnologies raised $90 million in a Series C after sharing early data for a new epigenetic approach to facioscapulohumeral muscular dystrophy (FSHD). The company said the funding will advance its lead therapy, EPI-321, toward pivotal clinical development after enrollment in an initial Phase I/II study. Epicrispr described FSHD as a disease target that may fit its Gene Expression Modulation System (GEMS) platform, citing a genetic driver involving DUX4 expression. The company said EPI-321 is designed for durable suppression of disease-causing gene expression using a single AAV vector, without permanently changing DNA sequence. The financing marks a shift from earlier fundraising focused on proving platform translation to a stage aimed at registrational execution. Epicrispr highlighted investor support from crossover healthcare and life science backers. For rare disease drug development, the deal emphasizes how epigenetic mechanisms are increasingly being framed as programmable and potentially one-time therapies, raising expectations for clinical durability endpoints.